Table 3.
Endogenous RRM1 levels and gemcitabine, pemetrexed, and carboplatin efficacy in 26 NSCLC cell lines.
| Cell Line | ATCC # | Histological Subtype* | p53 mutation (* = stop) based on CCDS11118.1 cod on 72 either proline or arginine | K-ras mutation | Doubling Time (hr) | RRM1 | RRM2a | RRM2b | ERCC1 | TS | TP53 | P38 | MCM2 | Gem IC50 (uM) | Pem IC50 (uM) | Carbo IC50 (uM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A549 | CLL-185 | AD-BAC | wt | G12S | 48 | 2.30 | 1.08 | 1.23 | 2.49 | 0.90 | 0.53 | 0.91 | 0.83 | 0.010 | 0.103 | 41.003 |
| ADLC5M2 | — | AD | wt | wt | 24 | 2.42 | 1.79 | 0.30 | 2.40 | 0.66 | 0.12 | 0.58 | 1.22 | 0.079 | 0.044 | 6.678 |
| EPLC65H | — | SQ | wt | wt | 47 | 2.83 | 1.07 | 0.55 | 3.92 | 1.23 | 0.12 | 1.22 | 0.97 | 0.019 | 0.039 | 7.590 |
| H125 | CRL-5801 | AD/SQ | N239* | wt | 70 | 1.65 | 2.53 | 1.05 | 3.64 | 0.60 | 0.00 | 0.92 | 0.87 | >1000 | 0.374 | 39.678 |
| H1299 | CRL-5803 | NSCLC-NOS | homozygous deletion | wt | 46 | 1.92 | 2.43 | 2.18 | 1.31 | 0.91 | 0.00 | 2.01 | 1.37 | 0.024 | 0.236 | 27.273 |
| H1355 | CRL-5865 | AD | E258K | G13C | 36 | 2.04 | 2.32 | 1.08 | 3.68 | 1.12 | 0.58 | 0.54 | 0.94 | 0.006 | 0.355 | 30.651 |
| H157 | CRL-5802 | SQ | E298* | G12R | 58 | 2.22 | 2.80 | 1.16 | 0.73 | 0.73 | 0.03 | 1.65 | 1.01 | 0.036 | 0.433 | 21.766 |
| H1648 | CRL-5882 | AD | frame shift codon 35;D42* | wt | 57 | 2.26 | 1.14 | 1.32 | 0.27 | 0.08 | 0.00 | 1.55 | 1.58 | >1000 | >1000 | 19.730 |
| H1650 | CRL-5883 | AD | wt | wt | 49 | 0.83 | 1.58 | 1.07 | 1.09 | 0.08 | 0.02 | 0.97 | 0.81 | 0.020 | 0.053 | 14.535 |
| H1703 | CRL-5889 | AD | wt | wt | 42 | 0.91 | 2.45 | 1.45 | 0.73 | 0.66 | 0.04 | 0.64 | 1.02 | 0.002 | 0.173 | 28.421 |
| H1975 | CRL-5908 | AD | R273H | wt | 39 | 1.94 | 2.24 | 1.05 | 0.13 | 0.15 | 1.01 | 1.25 | 1.05 | 0.145 | 0.051 | 19.250 |
| H2122 | CRL-5985 | AD | Q16L; C176F | G12C | 72 | 1.04 | 1.42 | 0.61 | 0.90 | 0.05 | 0.37 | 0.95 | 0.92 | >1000 | 0.054 | 56.217 |
| H2172 | CRL-5930 | NSCLC-NOS | frame shift codon 72;V122* | wt | 45 | 1.99 | 0.29 | 2.20 | 1.21 | 0.00 | 0.00 | 0.94 | 1.00 | 0.435 | 0.533 | 10.800 |
| H2228 | CRL-5935 | AD | Q331* | wt | 50 | 0.68 | 0.12 | 0.25 | 1.53 | 0.09 | 0.55 | 0.63 | 1.18 | 0.023 | 0.039 | 11.036 |
| H226 | CRL-5826 | SQ | wt | wt | 76 | 2.30 | 0.45 | 3.28 | 0.79 | 0.24 | 0.45 | 1.63 | 0.96 | 7.491 | >1000 | 37.317 |
| H23 | CRL-5800 | AD | M246I | G12C | 45 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.008 | 0.125 | 21.220 |
| H292 | CRL-1848 | ME | wt | wt | 31 | 2.11 | 1.90 | 1.13 | 2.08 | 0.93 | 0.61 | 1.26 | 0.73 | 0.011 | 0.026 | 30.326 |
| H322 | CRL-5806 | AD-BAC | R248L | wt | 36 | 1.26 | 1.65 | 1.06 | 1.65 | 0.38 | 0.72 | 0.76 | 1.02 | 0.016 | 0.118 | 41.434 |
| H358 | CRL-5807 | AD-BAC | homozygous deletion | G12C | 74 | 1.61 | 1.36 | 1.22 | 3.80 | 0.29 | 0.00 | 2.02 | 1.20 | 0.135 | 0.030 | 23.634 |
| H441 | HTB-174 | AD | R158L | G12V | 58 | 1.86 | 1.91 | 4.49 | 0.99 | 0.05 | 0.47 | 2.77 | 1.87 | 0.033 | 0.093 | 23.545 |
| H460 | HTB-177 | LC | wt | Q61H | 35 | 2.47 | 2.13 | 1.30 | 1.15 | 0.84 | 0.76 | 0.79 | 0.94 | 0.053 | 0.183 | 85.373 |
| H522 | CRL-5810 | AD | frame shift codon 191 with deletion of P | wt | 108 | 1.08 | 3.17 | 0.73 | 7.04 | 1.10 | 0.22 | 1.74 | 0.89 | >1000 | >1000 | 21.298 |
| H596 | HTB-178 | AD/SQ | G245C | wt | 49 | 1.61 | 1.98 | 1.00 | 3.00 | 0.53 | 0.68 | 1.25 | 0.93 | 0.031 | 0.012 | 28.626 |
| H650 | CRL-5835 | AD | K164N | wt | 83 | 1.25 | 1.34 | 1.57 | 1.55 | 0.13 | 0.66 | 0.77 | 0.91 | >1000 | >1000 | 32.422 |
| H661 | HTB-183 | LC | R158L; S215I | wt | 47 | 1.34 | 1.05 | 0.86 | 2.06 | 0.88 | 0.54 | 0.88 | 1.23 | 0.024 | >1000 | 57.253 |
| H820 | HTB-181 | AD | T284P | wt | 68 | — | — | — | — | — | — | — | — | 6.883 | >1000 | 32.116 |
*AD: adenocarcinoma, AD-BAC: adenocarcinoma with bronchoalveolar features, LC: large cell carcinoma, SQ: squamous cell carcinoma, ME: mucoepidermoid bronchial gland carcinoma, AD/SQ: mixed adenosquamous cell carcinoma, NSCLC-NOS: nonsmall cell lung cancer, not otherwise specified. IC50 values are the means of at least three experiments; 3–6 wells per experiment and dose level; 4,000 cells per well; 96 hr exposure.